Indications › Type 1 diabetes › semaglutide

semaglutide in type 1 diabetes

semaglutide is not approved in the US for type 1 diabetes, and has 11 trials on file here in this condition. 7 of them are phase 3 or later. The next scheduled result is 2027-01. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

11 registered trials study semaglutide (Ozempic, Rybelsus, Wegovy) in type 1 diabetes, 8 of them still active and 5 in phase 3. The next is due to report 2028-01-31.

Trials on file: 11
Active: 8
Active phase 3: 5
Participants in active trials: 2,601
Sponsors: 10
Scheduled readouts: 2

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2028-01-31	SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. NCT07614412 · Ministry of Health, Saudi Arabia	P2	240
2028-06	Semaglutide Treatment in Type 1 Diabetes NCT06909006 · Nordsjaellands Hospital	P3	122

All trials on file

Every registered trial of semaglutide grouped under type 1 diabetes, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes NCT06082063	Recruiting	P3	Steno Diabetes Center Copenhagen
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. NCT07614412	Not yet recruiting	P2	Ministry of Health, Saudi Arabia
Semaglutide Treatment in Type 1 Diabetes NCT06909006	Not yet recruiting	P3	Nordsjaellands Hospital
ADJUnct Semaglutide Treatment in Type 1 Diabetes NCT05537233	Completed	P2	Viral N. Shah
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients NCT05857085	Completed	P4	General and Teaching Hospital Celje
Triple Therapy in T1DM NCT03899402	Active, not recruiting	P2/P3	State University of New York at Buffalo
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes NCT05819138	Recruiting	P3	University of Colorado, Denver
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes NCT05822609	Recruiting	P2	University of Washington
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care NCT05205928	Completed	P2/P3	McGill University Health Centre/Research Institute of the McGill University Health Centre
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide NCT06387199	Recruiting	P2/P3	McGill University Health Centre/Research Institute of the McGill University Health Centre
GLP-1 RA for Stage 1 Type 1 Diabetes NCT07430332	Not yet recruiting	P2	Children's Hospital Medical Center, Cincinnati

See the full record for semaglutide, or every molecule being studied in type 1 diabetes. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.